VIDEO: Feng Zeng, PhD, Discusses Copayment Reduction in the Gap and Its Impact on Diabetes Medications

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with type 2 diabetes in the Blood Pressure Control Target in Diabetes trial.

On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.

Results bring more competition to treat this genetically driven target for cardiovascular risk.

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse events in patients less at risk of cardiomyopathy.

Follow-up results for the FINEARTS-HF trial focused on specific results for women and men, hyperkalemia risk, and an analysis of the elements of its composite end point.